Sree S. Kolli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sree S. Kolli has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Steven Richard Feldman
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
7 shared publications - Abigail Cline
Department of Dermatology, New York Medical College, New York, NY.
4 shared publications - Aditi Senthilnathan
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
4 shared publications Steven R. Feldman
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina
4 shared publicationsAdrian Pona
Wake Forest School of Medicine
3 shared publicationsRita O. Pichardo
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
3 shared publications
Latest Publications
- 29 September 2020
- Published by Springer Nature
- p. 35-51
Evidence-Based Management
- 1 March 2020
- Vol. 105 (3) , E32-E33
Is There an Association Between Hidradenitis Suppurativa and Fibromyalgia?
- 1 March 2020
- Vol. 105 (3) , E32-E33
Is There an Association Between Hidradenitis Suppurativa and Fibromyalgia?
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , 236-238
Hidradenitis suppurativa has an enormous impact on patients' lives
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , 236-238
Hidradenitis suppurativa has an enormous impact on patients' lives
- 1 October 2019
- Published by Elsevier in Dermatologic Clinics
- Vol. 37 (4) , 569-582
Review of Graft-Versus-Host Disease
- 1 October 2019
- Published by Elsevier in Dermatologic Clinics
- Vol. 37 (4) , 569-582
Review of Graft-Versus-Host Disease
- 10 September 2019
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 5 (6) , 366-369
Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory condition. Objective: To measure emotional well-being in HS patients and compare to other populations, assess if there is an effect of disease severity on emotional well-being, and determine if emotional well-being is correlated with quality of life and depression. Methods: A total of 153 HS subjects were recruited, and 66 Positive and Negative Affect Schedule (PANAS) surveys assessing emotional well-being were completed. Norms for comparison populations (disease-free undergraduates and adults) were used. A validated self-assessment tool was used to determine disease severity. Subjects completed the Patient Health Questionnaire-9 (PHQ-9) and Dermatology Life Quality Index (DLQI) to examine depression and quality of life, respectively. Results: HS subjects had lower positive affect than undergraduates and higher negative affect than adults. There were no differences in PANAS scores by Hurley stage (p > 0.05). PANAS scores for HS subjects correlated with worse quality of life (r = 0.66, p < 0.00001) and depression (r = 0.74, p < 0.00001). Conclusion: HS patients have poor emotional well-being. PANAS scores correlated with worse quality of life and depression. Providing appropriate resources and treatments may be beneficial for HS patients.
- 10 September 2019
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 5 (6) , 366-369
Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory condition. Objective: To measure emotional well-being in HS patients and compare to other populations, assess if there is an effect of disease severity on emotional well-being, and determine if emotional well-being is correlated with quality of life and depression. Methods: A total of 153 HS subjects were recruited, and 66 Positive and Negative Affect Schedule (PANAS) surveys assessing emotional well-being were completed. Norms for comparison populations (disease-free undergraduates and adults) were used. A validated self-assessment tool was used to determine disease severity. Subjects completed the Patient Health Questionnaire-9 (PHQ-9) and Dermatology Life Quality Index (DLQI) to examine depression and quality of life, respectively. Results: HS subjects had lower positive affect than undergraduates and higher negative affect than adults. There were no differences in PANAS scores by Hurley stage (p > 0.05). PANAS scores for HS subjects correlated with worse quality of life (r = 0.66, p < 0.00001) and depression (r = 0.74, p < 0.00001). Conclusion: HS patients have poor emotional well-being. PANAS scores correlated with worse quality of life and depression. Providing appropriate resources and treatments may be beneficial for HS patients.
- 17 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (5) , 1087-1088
Depression in hidradenitis suppurativa
- 17 May 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (5) , 1087-1088
Depression in hidradenitis suppurativa
- 14 May 2019
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 18 (6) , 523-536
A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data
Introduction: Psoriasis is a chronic, inflammatory condition whose management can include oral medications and injectable biologics. Safety data of these various treatment options are important to consider when choosing the right treatment for the patient. Areas covered: This review evaluates the safety of newer treatments approved for psoriasis, including interleukin-(IL)-17 inhibitors, IL-23/p19 inhibitors, ustekinumab, certolizumab pegol and apremilast, using phases III and IV clinical trial data. Expert opinion: Even as treatment of psoriasis becomes more effective and safer, it is important to recognize both common and uncommon adverse effects of treatment. Common adverse effects are similar across treatment options, including upper respiratory infection and injection-site reaction. Serious adverse effects occur less frequently and may be specific to the psoriasis treatment option, such as inflammatory bowel disease and candida infections with IL-17 inhibitors, tuberculosis with certolizumab pegol, and psychiatric events with apremilast. While IL-23/p19 inhibitors may have a slightly better safety profile than other biologics, long-term data are limited. Patients should be aware of both the common AEs to prevent premature discontinuation of treatment and the rare AEs to monitor for development of serious symptoms. The conclusions that can be drawn from clinical trial safety data are limited given that many clinical trials are not large enough to detect rare safety events, and there may be differences in safety experienced in clinical practice that are not well documented. Data from registries provide important complementary information on long-term safety but there are limitations including a lack of randomized assignment between drug treatments.
- 14 May 2019
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 18 (6) , 523-536
A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data
Introduction: Psoriasis is a chronic, inflammatory condition whose management can include oral medications and injectable biologics. Safety data of these various treatment options are important to consider when choosing the right treatment for the patient. Areas covered: This review evaluates the safety of newer treatments approved for psoriasis, including interleukin-(IL)-17 inhibitors, IL-23/p19 inhibitors, ustekinumab, certolizumab pegol and apremilast, using phases III and IV clinical trial data. Expert opinion: Even as treatment of psoriasis becomes more effective and safer, it is important to recognize both common and uncommon adverse effects of treatment. Common adverse effects are similar across treatment options, including upper respiratory infection and injection-site reaction. Serious adverse effects occur less frequently and may be specific to the psoriasis treatment option, such as inflammatory bowel disease and candida infections with IL-17 inhibitors, tuberculosis with certolizumab pegol, and psychiatric events with apremilast. While IL-23/p19 inhibitors may have a slightly better safety profile than other biologics, long-term data are limited. Patients should be aware of both the common AEs to prevent premature discontinuation of treatment and the rare AEs to monitor for development of serious symptoms. The conclusions that can be drawn from clinical trial safety data are limited given that many clinical trials are not large enough to detect rare safety events, and there may be differences in safety experienced in clinical practice that are not well documented. Data from registries provide important complementary information on long-term safety but there are limitations including a lack of randomized assignment between drug treatments.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 345-346
Treatment-resistant prurigo nodularis
Treatment-resistant prurigo nodularis Sree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Dear editorKowalski et al describe various treatment approaches to achieve better outcomes in treatment-resistant prurigo nodularis in an article entitled, “Treatment-resistant prurigo nodularis: challenges and solutions.”1 Many excellent approaches are suggested, but the issue of nonadherence to topical therapies may be an overlooked issue commonly contributing to “treatment-resistance.” Often, in the face of “resistant” disease, patients may be prescribed more complicated or risky treatment regimens that make adherence even more difficult. Such strategies may not be the most effective ones when poor adherence underlies seemingly treatment-resistant prurigo nodularis.Treatment-resistance can often be overcome by measures that improve adherence. Even patients with severe, refractory atopic dermatitis respond rapidly to midpotency topical corticosteroids applied in the inpatient setting. Prurigo nodularis is often secondary to atopic dermatitis and psoriasis. In patients with atopic dermatitis or psoriasis that was “resistant” to topical corticosteroids, all patients treated with an easy to use topical corticosteroid spray improved rapidly when coupled with adherence promoting measures (telephone reminders, patient education and frequent office visits). Adherence to topical treatments is bad in the short-term and abysmal in the long-term.2–4 Perhaps one of the best approaches when faced with treatment-resistant disease is to simplify the treatment regimen and encourage good use of treatment, or better yet, bring patients in to assure the treatment is administered.
- 1 May 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 345-346
Open AccessTreatment-resistant prurigo nodularis
Treatment-resistant prurigo nodularis Sree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Dear editorKowalski et al describe various treatment approaches to achieve better outcomes in treatment-resistant prurigo nodularis in an article entitled, “Treatment-resistant prurigo nodularis: challenges and solutions.”1 Many excellent approaches are suggested, but the issue of nonadherence to topical therapies may be an overlooked issue commonly contributing to “treatment-resistance.” Often, in the face of “resistant” disease, patients may be prescribed more complicated or risky treatment regimens that make adherence even more difficult. Such strategies may not be the most effective ones when poor adherence underlies seemingly treatment-resistant prurigo nodularis.Treatment-resistance can often be overcome by measures that improve adherence. Even patients with severe, refractory atopic dermatitis respond rapidly to midpotency topical corticosteroids applied in the inpatient setting. Prurigo nodularis is often secondary to atopic dermatitis and psoriasis. In patients with atopic dermatitis or psoriasis that was “resistant” to topical corticosteroids, all patients treated with an easy to use topical corticosteroid spray improved rapidly when coupled with adherence promoting measures (telephone reminders, patient education and frequent office visits). Adherence to topical treatments is bad in the short-term and abysmal in the long-term.2–4 Perhaps one of the best approaches when faced with treatment-resistant disease is to simplify the treatment regimen and encourage good use of treatment, or better yet, bring patients in to assure the treatment is administered.
- 27 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (4) , 838-839
Even mild hidradenitis suppurativa impairs quality of life
- 27 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (4) , 838-839
Even mild hidradenitis suppurativa impairs quality of life